Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
6.36
-0.24 (-3.63%)
Apr 27, 2026, 10:40 AM EDT - Market open
Plus Therapeutics Employees
Plus Therapeutics had 28 employees as of December 31, 2025. The number of employees increased by 7 or 33.33% compared to the previous year.
Employees
28
Change (1Y)
7
Growth (1Y)
33.33%
Revenue / Employee
$186,179
Profits / Employee
-$799,500
Market Cap
43.64M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 28 | 7 | 33.33% |
| Dec 31, 2024 | 21 | 1 | 5.00% |
| Dec 31, 2023 | 20 | 3 | 17.65% |
| Dec 31, 2022 | 17 | 3 | 21.43% |
| Dec 31, 2021 | 14 | 2 | 16.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Xilio Therapeutics | 76 |
| Mereo BioPharma Group | 39 |
| Sensei Biotherapeutics | 15 |
| Rallybio | 14 |
| Nutriband | 13 |
| Rein Therapeutics | 10 |
| Hyperion DeFi | 9 |
| Dogwood Therapeutics | 8 |
PSTV News
- 4 days ago - Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ - GlobeNewsWire
- 4 days ago - Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 12 days ago - Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution - GlobeNewsWire
- 18 days ago - Plus Therapeutics Appoints Eric J. Daniels, M.D. - GlobeNewsWire
- 19 days ago - Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas - GlobeNewsWire
- 20 days ago - Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption - GlobeNewsWire
- 25 days ago - Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives - GlobeNewsWire